Document Detail

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
MedLine Citation:
PMID:  18625618     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To develop a new index for disease activity in ankylosing spondylitis (ASDAS) that is truthful, discriminative and feasible, and includes domains/items that are considered relevant by patients and doctors. METHODS: Eleven candidate variables covering six domains of disease activity, selected by ASAS experts in a Delphi exercise, were tested in a three-step approach, similar to the methodology used for the disease activity score in rheumatoid arthritis. Data on 708 patients included in ISSAS (International Study on Starting tumour necrosis factor blocking agents in Ankylosing Spondylitis) were used. Cross validation was carried out in the OASIS cohort (Outcome in Ankylosing Spondylitis International Study). RESULTS: Principal component analysis disclosed three factors with eigenvalues >0.75: patient assessments, peripheral joint assessments and acute phase reactants. Discriminant function analysis resulted in a correct classification in approximately 72% of the cases (prior probability approximately 50%). Regression analysis resulted in an index with five variables (total back pain, patient global assessment, duration of morning stiffness, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)). Three additional candidate indices were designed using similar methodology while omitting either ESR or CRP or patient global assessment. All four scores correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; r = 0.67-0.80), patient (0.58-0.75) and physician's global assessment (0.41-0.48) of disease activity. All four candidate ASDAS indices performed better than BASDAI or single-item variables in discriminating between high and low disease activity state, according to doctors as well as patients in the OASIS cohort. CONCLUSION: The first steps in the development of a new assessment tool of disease activity in AS derived four candidate indices with good face and construct validity, and high discriminant capacity.
C Lukas; R Landewé; J Sieper; M Dougados; J Davis; J Braun; S van der Linden; D van der Heijde;
Related Documents :
17994238 - Diagnostic imaging of gout: comparison of high-resolution us versus conventional x-ray.
1395248 - The long-term course of various meniscal treatments in anterior cruciate ligament defic...
3685908 - The importance of skin vessel wall immune deposits in the course of the systemic and ar...
2357498 - Articular involvement in european patients with lyme disease. a report of 32 italian pa...
11834668 - Role of fine-needle aspirates of focal lung lesions in patients with hematologic malign...
9670348 - Development of play-the-winner design: weighting and accumulation of information.
Publication Detail:
Type:  Journal Article; Validation Studies     Date:  2008-07-14
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  68     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-17     Completed Date:  2009-01-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  18-24     Citation Subset:  IM    
University Hospital and CAPHRI Research Institute, Maastricht 6202 AZ, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Back Pain / physiopathology
Blood Sedimentation
C-Reactive Protein / analysis
Chronic Disease
Delphi Technique
Disability Evaluation*
Discriminant Analysis
Principal Component Analysis
Regression Analysis
Severity of Illness Index
Spondylitis, Ankylosing / blood,  physiopathology*
Reg. No./Substance:
9007-41-4/C-Reactive Protein
Comment In:
Ann Rheum Dis. 2009 Jan;68(1):1-2   [PMID:  19088258 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middl...
Next Document:  Testing the druggable endothelial differentiation gene 2 knee osteoarthritis genetic factor for repl...